Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
| Autor: | Stefano Rusconi, Anna Rita Buonomini, A Di Pietro, Gabriella d'Ettorre, C. Abeli, M. D’Annunzio, Amedeo Capetti, M Capasso, Chiara Tommasi, Alessandro Soria, Emanuele Focà, Giulia Marchetti, G. Orofino, Stefano Bonora, Paola Vitiello, Paola Meraviglia, S Farina, MP Trotta, Elisa Colella, Fulvio Adorni, Esther Merlini, L. Butini, A. Di Biagio, Daniela Francisci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
business.industry virologic response HIV immunological response HAART Maraviroc Public Health Environmental and Occupational Health Human immunodeficiency virus (HIV) Viremia CD38 medicine.disease medicine.disease_cause Gastroenterology Non responders chemistry.chemical_compound Infectious Diseases Pharmacotherapy Acquired immunodeficiency syndrome (AIDS) chemistry Internal medicine Immunology medicine Oral Presentation business CD8 |
| Zdroj: | Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, 7-11 November 2010 info:cnr-pdr/source/autori:S Rusconi, P Vitiello, F Adorni, E Colella, E Focà, AF Capetti, P Meraviglia, C Abeli, S Bonora, M D'Annunzio, A Di Biagio, A Di Pietro, L Butini, G Orofino, S Farina, G d'Ettorre, D Francisci, A Soria, AR Buonomini, C Tommasi, MP Trotta, M Capasso, E Merlini, GC Marchetti/congresso_nome:Tenth International Congress on Drug Therapy in HIV Infection/congresso_luogo:Glasgow/congresso_data:7-11 November 2010/anno:2010/pagina_da:/pagina_a:/intervallo_pagine Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| Popis: | Purpose: 15-30% of HAART-treated HIV-1-positive patients (pts) lack CD4+ increase despite full HIV viremia suppression. The increased risk for INR to progress till AIDS led us to investigate maraviroc (MVC) as a tool to intensify HAART in terms of immunological recovery. Methods: Randomised, multicentre, proof-of-concept study enrolling 100 pts divided into 2 arms (1:1), A:HAART+MVC, B:HAART. Inclusion criteria were: CD4 count ≥200 cells/µL and/or a recovery of CD4 cells |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink